Core Viewpoint - The Ultragenyx class action lawsuit alleges that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab, leading to significant stock price declines when the truth was revealed [4][5][6]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta (OI) patients and downplayed the risks associated with the Phase III Orbit study [4]. - It is alleged that Ultragenyx's optimism regarding the Phase III Orbit study was unfounded, as the results were based on Phase II data without a placebo control group, which could have led to misleading conclusions about the drug's effectiveness [4]. Stock Price Impact - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by over 25% [5]. - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by more than 42% [6]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the Class Period to seek appointment as lead plaintiff in the class action lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is recognized for recovering over $916 million for investors in 2025 and has a strong track record in securities class action recoveries, totaling $8.4 billion over the past five years [8].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, alleging that the company misled investors regarding the Phase III Orbit and Cosmic Studies for setrusumab [1][2]. Allegations - The lawsuit claims that during the class period, Ultragenyx provided investors with overly positive information about the expected results of the Phase III Orbit and Cosmic Studies, which tested setrusumab in patients with Osteogenesis Imperfecta (OI) [2]. - Defendants allegedly expressed confidence in setrusumab's ability to reduce the annualized fracture rate in OI patients and in the study designs to demonstrate this ability, while concealing material adverse facts about the drug's true potential and the risks associated with the study protocols [3]. Study Results and Impact - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in just one day [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action against Ultragenyx are encouraged to contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [5].

Market Overview - The S&P 500 fell 0.51% to 6,882.72, while the Nasdaq Composite slid 1.51% to 22,904.58 due to heavy tech selling. The Dow Jones Industrial Average rose 0.53% to 49,501.30 as investors shifted towards defensive and value stocks [1] Company Performance - Advanced Micro Devices (AMD) experienced a significant drop of 17.31% despite reporting solid earnings, closing at $200.19. The company's Q1 forecast did not meet high market expectations [2] - Software stocks, including Thomson Reuters, saw substantial declines, with Thomson Reuters down over 20% in the past five days. Conversely, biopharmaceutical company Amgen gained over 8% on positive Q4 results, contributing to the Dow's positive performance [3] Market Sentiment - The Nasdaq's decline reflects skepticism towards AI, highlighted by the steep sell-off of AMD. SanDisk also fell nearly 16%, erasing recent gains. The release of new AI tools by Anthropic is pressuring software and services companies, leading to a loss of around $300 billion in software and financial services stocks [4] - The tech upheaval is causing capital to rotate towards defensive and cyclical stocks, as evidenced by the Dow's gains. Disappointing jobs data from ADP, which reported only 22,000 private payroll additions in January against a forecast of 45,000, has added to investor uncertainty [5]

Core Viewpoint - Vanda Pharmaceuticals Inc. will release its financial results for the fourth quarter and full year 2025 on February 11, 2026, after market close [1]. Group 1: Financial Results Announcement - The financial results will be discussed during a conference call scheduled for 4:30 PM ET on February 11, 2026 [2]. - The conference call will be accessible via a domestic dial-in number (1-888-596-4144) and an international number (1-646-968-2525) with a passcode of 8728050 [2]. Group 2: Conference Call Details - The conference call will be broadcast live and archived on Vanda's website, encouraging investors to register and prepare in advance [3]. - A replay of the conference call will be available starting at 8:30 PM ET on February 11, 2026, until 11:59 PM ET on February 18, 2026, with specific call-in numbers for domestic (1-800-770-2030) and international (1-609-800-9909) callers [4]. Group 3: Company Overview - Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to meet high unmet medical needs [5].

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025 [1][2]. - Allegations include that Vistagen provided misleading statements about the success of its Phase 3 PALISADE-3 trial for fasedienol while concealing adverse facts [2][3]. Group 2: Trial Results and Impact - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show statistically significant improvement on its primary endpoint, leading to a dramatic stock price drop from $4.36 to $0.86, a decline of over 80% [3]. Group 3: Next Steps for Investors - Shareholders wishing to serve as lead plaintiffs must submit their papers by March 16, 2026, but participation is not required to be eligible for recovery [4].

As filed with the Securities and Exchange Commission on February 4, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (8 ...

Core Insights - NorthStrive Biosciences, a subsidiary of PMGC Holdings, has provided an update on the timeline for Phase III of its AI Development Program in collaboration with Yuva Biosciences, with results expected in Q2 2026 [1][3] Group 1: Company Updates - NorthStrive Biosciences initiated Phase III of its AI Development Program on December 17, 2025, which is anticipated to last approximately 6 to 9 weeks [1] - Yuva Biosciences has developed improved sixth-generation classifier models that enhance screening accuracy and sensitivity, which will be utilized in the Phase III study [2] - The extended timeline for Phase III results is expected to yield more robust and reliable outcomes to support further development efforts [3] Group 2: Company Background - Yuva Biosciences specializes in mitochondrial sciences and employs advanced AI to identify therapeutic candidates targeting aging-related pathways, with its proprietary platform MitoNova™ [4] - NorthStrive Biosciences focuses on developing aesthetic medicines, with its lead asset EL-22 aimed at addressing obesity while preserving muscle during weight loss treatments [5] - PMGC Holdings is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [6]

Core Insights - Viking Therapeutics, Inc. is set to release its financial results for Q4 and year-end 2025 on February 11, 2026, after market close [1] - A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss these results and provide corporate updates [2] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3] - The company is advancing several clinical programs, including VK2735, a dual agonist for GLP-1 and GIP receptors, currently in Phase 3 trials for obesity [3] - VK2809, another key program, is an orally available small molecule for treating lipid and metabolic disorders, having met primary and secondary endpoints in a Phase 2b study for NASH [3] - The company is also developing VK0214 for X-ALD, which has shown safety and efficacy in reducing VLCFAs in a Phase 1b trial [3]

Core Viewpoint - Ascendis Pharma A/S plans to report its full year 2025 financial results and provide a business update on February 11, 2026, after the U.S. financial markets close [1] Group 1: Financial Reporting - The company will host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss the 2025 financial results [1] - Participants can access the live webcast through a provided link or register in advance for the teleconference [2] Group 2: Company Overview - Ascendis Pharma is focused on applying its innovative TransCon technology platform to create new and potentially best-in-class therapies [3] - The company is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States [3]

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - CEO Andrew Obenshain will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, in New York City [1][2] Company Overview - Inventiva is engaged in the research and development of oral small molecule therapies targeting MASH and other diseases with significant unmet medical needs [2] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for adult patients with MASH [2] Stock Information - Inventiva is publicly listed on Euronext Paris (ticker: IVA) and the Nasdaq Global Market in the United States (ticker: IVA) [3]